WCN26-4399 KIDNEY-ALONE TRANSPLANTATION WHILE ON siRNA THERAPY FOR PRIMARY HYPEROXALURIA TYPE 1: A MULTINATIONAL RETROSPECTIVE CASE SERIES FROM THE PH1NITx WORKING GROUP

Read full text Summarise with VIRAT
Authors: Atessa Bahadori, Anne‐Laure Sellier‐Leclerc, Nithikishna Selvathesan, Vladimir Belostotsky, Istvan Mucsi, Asma Nasir, Sander Frederik Garrelfs, Bernd Höppe, Chia Wei Teoh, Justine Bacchetta, Mathieu J. Lemaire, Atessa Bahadori
+45 more Anne‐Laure Sellier‐Leclerc, Nithiakishna Selvathesan, Alanoud Alshami, Dany Anglicheau, Barbara Buscemi, Carmen Ávila-Casado, Michelle Baum, Efrat Ben‐Shalom, Matthew Clarence Breeggemann, Vladimir Belostotsky, Chiara Caletti, Christopher T. Chan, Déborah Chaintreuil, Stéphanie Clave, Mariella D'Alessandro, Pietro Manuel Ferraro, Daniel Guido Fuster, William P. Hanf, Elizabeth A. Harvey, Wesley Nathan Hayes, Hebatallah Bahbah, Alexandre Karras, Alice Koenig, Yannis Lombardi, Armando José Lorenzo, Marie Matignon, Ashlene Maree McKay, Istvan Mucsi, Asma Nasir, Peggy Perrin, Andrea Ranghino, Alexander Ritter, Franz Schaefer, Peter Schulga, Michael J.G. Somers, Thomas Stehle, Doug Stewart, Hillarey K. Stone, Charles D. Varnell, Nicole Wintsch, Sander Frederik Garrelfs, Bernd Höppe, Chia Wei Teoh, Justine Bacchetta, Mathieu J. Lemaire
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Primary hyperoxaluria type 1 (PH1) is a rare genetic disease characterized by systemic oxalate deposition and progressive kidney failure. Expert guidelines currently recommend liver-kidney transplantation (LKTx) for PH1 patients with kidney failure (KF) unresponsive to vitamin B6 therapy, a procedure with a 1-year mortality rate of up to 5–15%, primarily due to severe infections. In conjunction with intensive hyperhydration and urine alkalinization, the treatment landscape for PH1 has recently shifted with the advent of RNA interference (siRNA) therapies targeting hepatic oxalate production.

Fields of Study & Subjects

Kidney Stones and Urolithiasis Treatments Renal Transplantation Outcomes and Treatments Organ Transplantation Techniques and Outcomes

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105115–105115
Publication date
25 March 2026
Language
EN